Additionally, Madan et al. evidenced that LTBI patients with COVID-19 had significantly higher lymphocyte and monocyte percentages, lower C-reactive protein, lesser radiologic involvement, and a milder COVID-19 clinical course in comparison with patients without LTBI [27]. The gene discussed is CRP; the disease is COVID-19.